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Abstract 
Background 
Riluzole is a neuroprotective drug used in the treatment of motor neurone disease. Recent 
evidence suggests that riluzole can up-regulate the expression and activity of the astrocyte 
glutamate transporter, GLT-1. Given that regulation of glutamate transport is predicted to be 
neuroprotective in Parkinson’s disease, we tested the effect of riluzole in parkinsonian rats 
which had received a unilateral 6-hydroxydopamine injection into the median forebrain 
bundle. 
Results 
Rats were treated with intraperitoneal riluzole (4 mg/kg or 8 mg/kg), 1 hour before the lesion 
then once daily for seven days. Riluzole produced a modest but significant attenuation of 
dopamine neurone degeneration, assessed by suppression of amphetamine-induced rotations, 
preservation of tyrosine hydroxylase positive neuronal cell bodies in the substantia nigra pars 
compacta and attenuation of striatal tyrosine hydroxylase protein loss. Seven days after 6-
hydroxydopamine lesion, reactive astrocytosis was observed in the striatum, as determined by 
increases in expression of glial fibrillary acidic protein, however the glutamate transporter, 
GLT-1, which is also expressed in astrocytes was not regulated by the lesion. 
Conclusions 
The results confirm that riluzole is a neuroprotective agent in a rodent model of parkinson’s 
disease. Riluzole administration did not regulate GLT-1 levels but significantly reduced 
GFAP levels, in the lesioned striatum. Riluzole suppression of reactive astrocytosis is an 
intriguing finding which might contribute to the neuroprotective effects of this drug. 
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Background 
The primary pathological event in Parkinson’s disease is degeneration of the nigrostriatal 
dopamine neurons. In Parkinson’s disease, corticostriatal and subthalamonigral glutamate 
systems are hyperactive, and contribute to symptoms and dopamine neuronal death, through 
the process of “excitotoxicity” [1-3]. Reducing glutamate transmission through activating 
type III metabotropic glutamate receptors [2,4], blocking type I metabotropic glutamate 
receptors [5], or blocking postsynaptic AMPA or NMDA receptors [6,7] have been shown to 
be neuroprotective and reduce motor symptoms in animal models of Parkinson’s disease. In 
general, therefore, anti-glutamate approaches are attractive and promising therapeutically, 
although they have not yet led to effective clinical drugs. 
One potential way of regulating glutamate levels, which has been largely overlooked in 
Parkinson’s disease, is by modulating astrocytes. Astrocytes express glutamate transporters 
which remove glutamate from the synaptic cleft and thus control the duration and magnitude 
of glutamate’s actions [8]. In Parkinson’s disease astrocytes show features typical of reactive 
astrocytosis [9]. In animal models of Parkinson’s disease, astrocytes are also markedly 
altered: following dopamine neurone degeneration astrocytes become reactive, as seen by a 
sustained and progressive increase in the levels of the astrocyte cytoskeletal protein, glial 
fibrillary acidic protein (GFAP) together with changes in astrocyte morphology [10-12]. 
Since reactive astrocytosis is associated with loss of the protective functions in astrocytes 
[13], suppression of astrocyte reactivity may be beneficial in disease. 
We recently identified the clinically used neuroprotective compound, riluzole, as a positive 
modulator of the major astrocyte glutamate transporter, GLT-1, in vitro [14]. Riluzole has 
already been through a number of clinical trials in Parkinson’s disease patients [15-17]. The 
largest clinical study published to date was a double-blind study with 20 patients with early 
Parkinson’s disease, untreated with L-dopa who received 100 mg riluzole per day for up to 
one year [17]. Here riluzole did not produce any significant improvement in disability or 
reduce the time before patients commenced dopamine agonist therapy, however the effects of 
riluzole on disease progression were not assessed. We therefore tested riluzole in the 6-
hydroxydopamine (6-OHDA) treated rat model of Parkinson’s disease to determine whether 
it can cause neuroprotection and whether protection was associated with modulation of GLT-
1 expression in astrocytes. 
Results 
Due to the functional deficit of dopamine transmission on the ipsilateral, lesion hemisphere 
following unilateral 6-OHDA lesion, animals show a high level of ipsiversive rotation when 
challenged with amphetamine (Figure 1A). Riluzole produced a significant, dose-dependent 
reduction in this effect, indicating functional preservation of the dopaminergic system. In 
support of this behavioural evidence, immunostaining revealed that riluzole (8 mg/kg, but not 
4 mg/kg) significantly protected TH positive cells in the substantia nigra pars compacta from 
6-OHDA induced cell death (Figure 1B, C). In vehicle treated animals, there were an average 
of 81 ± 6.6 cells (n = 8) counted on the unlesioned side, compared to 27 ± 2.1 cells on the 
lesioned side (n = 9). Riluzole (8 mg/kg) reduced the 6-OHDA-induced cell loss on the 
ipsilateral side from 66.1 ± 2.6 % (n = 8) to 55.8 ± 4.5 % (n = 8) (p < 0.05). Analysis of 
Western blots showed that riluzole (8 mg/kg) was able to partially preserve striatal TH levels 
from lesion-induced depletion (Figure 1E–F): after riluzole administration, the amount of TH 
remaining on the side ipsilateral to the lesion was approximately 4 times higher than when 
vehicle was administered. 
Figure 1  Neuroprotective effects of riluzole (4 or 8 mg/kg) given 1 hour before and for 7 
days post-lesion in the 6-OHDA rat model of PD. A. Effect of riluzole or vehicle on 
ipsilateral rotations in lesioned rats measured between 25–70 minutes after amphetamine 
administration. B. Tyrosine Hydroxylase (TH) immunoreactive neurones in the substantia 
nigra pars compacta (SNpc), scale bar = 0.5 mm. C shows quantification of TH positive cells 
in SNpc on the side ipsilateral to the lesion ± SEM, expressed as a % of the unlesioned, intact 
side (n = 8 per group), * = p < 0.05, One-Way Anova followed by Bonferroni’s test. D. 
Sections at the level of the striatum stained for TH immunoreactivity. E. Western blot data 
shows loss of TH immunoreactivity on lesioned side which is reduced in animals treated with 
riluzole (8 mg/kg). F shows these data quantified: for each animal the TH band intensity is 
divided by the band density of a housekeeping protein, β-tubulin and expressed as % of the 
intact side ± SEM (n = 8), * = p < 0.05, unpaired t-test 
We next examined the astrocyte response to unilateral 6-OHDA lesion at 8 days after lesion, 
and the effect of riluzole administration. Immunostaining of sections suggested that 6-OHDA 
lesion caused no change in the expression of the glutamate transporter, GLT-1 in the striatum 
on the lesioned side (Figure 2A,B), although it caused a prominent increase in reactive 
astrocytes, as determined by GFAP immunostaining (Figure 2C,D). Western blotting 
confirmed these observations: there was no change in the striatal levels of GLT-1 protein 
following lesions that produced complete loss of tyrosine hydroxylase, and upregulated 
striatal GFAP (Figure 2E). 
Figure 2 Effect of 6-OHDA on neurochemical markers in striatum. Panels A-D are 
photomicrographs of striatum seven days following 6-OHDA administration, showing GLT-1 
immunostaining in striatum on lesioned (A) and intact (B) side and GFAP immunostaining – 
green on lesioned (C) and intact (D) side. Scale bar = 50 μm. E shows Western blots of 
striatal protein samples taken from 6-OHDA lesioned animals. Blots from two animals are 
shown for comparison. Membranes were blotted with antibodies against tyrosine hydroxylase 
(TH), GLT-1, GLAST, GFAP or beta-tubulin (βtub). Molecular weights (KDa) of protein 
bands are indicated, the glutamate transporters GLT-1 and GLAST are found as monomeric 
(67KDa) and multimeric (ca. 190 KDa) species 
Figure 3 shows the quantification of the effect of lesion and/or riluzole treatment on GFAP, 
GLT-1 and GLAST. As shown in Figure 3A, 6-OHDA lesion caused an increase in GFAP 
protein on the striatum on the lesioned side to 166 ± 8 % (n = 8, p < 0.01) compared to the 
intact side (Figure 3A). In animals treated with riluzole (4 or 8 mg/kg/day), there was still a 
significant increase in GFAP levels on the lesioned side compared to the intact side, however 
the increase in striatal GFAP on the side of the lesion was significantly reduced in animals 
treated with 4 mg/kg/day riluzole compared to vehicle treated animals by 31 ± 9 % (n = 9, p 
<0.05). Treatment of lesioned animals with 8 mg/kg/day riluzole also suppressed lesion-
induced elevation of GFAP by 17 ± 9%, though this increase was not statistically significant. 
In these animals, GLT-1 levels were unaffected by lesion and/or riluzole treatment (Figure 
3B). GLAST levels were unaffected by lesion or by treatment with riluzole (data not shown). 
Figure 3 Effect of riluzole on astrocyte protein expression in the striata of animals 
bearing a 6-OHDA lesion. Western blots were quantified, and band density of GFAP, GLT-
1 and GLAST calculated relative to the housekeeping protein, β-tubulin. Graphs show the 
relative expression levels of each of these proteins on the intact side (open bars) and lesioned 
side (filled bars) in 6-OHDA lesioned animals ± SEM (n = 8–9) ** = p <0.01 compared to 
vehicle-treated intact side, † = p <0.05 compared to vehicle-treated lesioned side 
Discussion 
We tested riluzole for its ability to confer neuroprotection in the 6-hydroxydopamine rat, an 
animal model of Parkinson’s disease. Our finding, that riluzole protects dopamine neurones 
from cell death confirms and extends the data reported in rats with a unilateral 6-OHDA (6 
μg) lesion which showed that a single riluzole injection (8 mg/kg) before lesion, and one 
twenty-four hours afterwards suppressed apomorphine or amphetamine-induced rotations and 
significantly reduced the loss of dopamine in the striatum [18]. Riluzole has also consistently 
been demonstrated to provide neuroprotection in MPTP-treated mice, when administered 
before the lesion [19-21]. In non-human primates riluzole administration either 1 hour prior 
to, or one hour after MPTP administration, followed by additional administrations also 
caused neuroprotection [22-25]. Our data therefore confirms that riluzole is an effective 
neuroprotective agent, at least when administration commences 1 h before the experimental 
lesion. 
Motor symptoms of Parkinson’s Disease appear when around 60-70% of the nigrostriatal 
tract has degenerated, in this study a partial lesion was used to mimic early stage Parkinson’s 
Disease, when neuroprotective strategies might be employed in the clinic. Such lesions have 
been successfully adopted in other studies of this kind in our lab [26]. Nevertheless, we 
acknowledge that there are limitations to the animal model used, not least because the 
protective drug is administered before lesioning. This pre-lesion administration is not 
clinically relevant but helps identify whether particular drug targets and mechanisms are 
likely to be effective if appropriate timing of administration can be achieved with better pre-
symptomatic diagnosis, and is a protocol employed in many studies. The currently available 
animal models are an acknowledged limitation in the field [27]. The rapidity of cell death 
which occurs following experimental administration of dopamine neurotoxins means that the 
true mechanisms underlying dopamine cell death are still being debated. 
The current study reveals a significant, but modest, neuroprotection when measured by 
protection of tyrosine hydroxylase positive cells, yet a larger reduction in behavioural 
rotations. As recently reviewed [27], behavioural responses, including amphetamine-induced 
rotation readouts obtained from animals bearing a partial lesion of the type used here can be 
rather variable. Thus, although amphetamine induces ipsiversive rotations, this may be seen 
in as few as half the animals tested [28], and the degree of rotation does not always change in 
direct relation to the degree of cell loss across a wide range of between 50-90% [29-31]. In 
our study, protection from 66 to 56% cell loss is reflected in a significant reduction in 
amphetamine-induced rotations, making it a useful, but not sole indicator of the degree of 
neuroprotection achieved. However, this result signifies that even a modest degree of cell 
protection, as achieved here, can manifest as functional improvement in motor behaviour if 
the resultant level of cell preservation moves beyond the threshold for symptom generation. 
While efficacious in rodent and primate models, riluzole has not proved clinically useful in 
patients with Parkinson’s disease [17]. The apparent discrepancy between the data sets most 
likely relates to the doses used. While it is difficult to accurately scale doses from humans to 
lower species, the riluzole doses used in this study (4 mg/kg or 8 mg/kg), typical of the doses 
required to produce positive effects in rodents [25,32], are five to ten fold higher than the 
dose of riluzole used clinically for the treatment of Amyotrophic Lateral Sclerosis/Motor 
Neuron Disease (ALS/MND). In ALS/MND patients, 50 mg twice daily is administered, i.e. 
between 1–2 mg/kg. This dose has been evaluated as providing the best benefit:risk ratio in 
ALS/MND [33], though doses of up to 200 mg/day are tolerated [33,34]. Riluzole doses such 
as those used clinically have never been reported to be effective in primate models of 
Parkinson’s disease, indeed the primate data suggests that higher doses of riluzole, between 
4–10 mg/kg daily are required for efficacy [22-25], i.e. equivalent to a dose range in man 
between 200 mg/day and 1 g/day. A 100 mg/day dose was shown to be ineffective in a 
clinical trial in patients with Parkinson’s disease [17], no dose-ranging was carried out, and it 
is unknown whether higher doses would provide benefit. It is possible, therefore, that in 
patients an efficacious riluzole concentration may not have been achieved, through concerns 
about the adverse effects of higher doses. Though riluzole itself, because of its tolerability in 
man, may never be effective in Parkinson’s disease, the proof of concept obtained in rodent 
and primate studies, including this one suggests that the drug is targeting a mechanism which 
is important in disease progression, thus suggesting routes for future therapies. 
Riluzole’s neuroprotective effects are generally regarded to be caused by its effects on 
reducing glutamate release in neurones following inhibition of voltage-gated sodium cation 
channels [35]. However, sodium channel blockers such as lamotrigine are ineffective in 
animal models of PD [36]. In addition, riluzole has additional, incompletely-characterised 
pharmacological effects which may be independent of effects on the persistent sodium 
current e.g. [37]. Since we had demonstrated that riluzole increases levels and activity of the 
glutamate transporter GLT-1 in primary cultures of striatal astrocytes [14], we reasoned that 
this transporter may be regulated by riluzole in vivo. However this study clearly demonstrates 
that riluzole does not regulate GLT-1 within one week of this partial 6-OHDA lesion. 
Our data shows that, even though striatal astrocytes become reactive following 6-OHDA 
lesion there is no regulation of GLT-1 protein levels. This observation is unexpected and 
contrasts to the loss of GLT-1 found in reactive astrocytes in vivo in other animal models of 
neurodegeneration, for example a transgenic model of motor neurone disease [38]. The 
underlying mechanisms which determine extent of loss of GLT-1 in reactive astrocytes are 
incompletely understood, but are likely to relate to the extent of astrocyte activation and the 
degree of preservation of the afferent input to astrocytes, which support continued GLT-1 
expression [39]. In the current study, we find GLT-1 to be neither up- nor down- regulated 
following 6-OHDA lesion, here measured 7 days after initial lesion. This is similar to the 
observations by others that there is no change in GLT-1 mRNA following striatal 6-OHDA 
lesion of rats [40] or in MPTP-treated mice [41]. However, there is some controversy on this 
issue; a recent well-controlled study shows that GLT-1 is upregulated after unilateral 6-
OHDA lesions (16 μg) in rats 3 weeks and 12 weeks, but not 5 weeks after lesion [42], and 
the changes when present were found bilaterally, i.e. on the lesioned and unlesioned side, 
even though GFAP was significantly increased only in the striatum on the lesioned side. 
There are other studies which suggest that glutamate uptake activity [43] and GLT-1 protein 
is down-regulated after more substantial 6-OHDA lesions [44], or after MPTP treatment of 
mice [10]. We cannot resolve these apparent discrepancies at this time, though note there are 
differences in the lesion protocols: in this study we chose a partial lesion that resulted in 
around 60% depletion of striatal TH, nor did we analyse the striatum at later time points, 
when later changes may potentially occur. We note that, in the animals used in this study, the 
degree of activation of astrocytes is likely to be relatively mild compared to studies with a 
more complete dopamine neurone lesion. 
Following 6-OHDA lesion there was a significant elevation of the astrocyte marker, GFAP, 
as expected [10-12]. Increased GFAP is usually interpreted as a marker of reactive 
astrogliosis, a phenotypic changes which include increased GFAP expression and elaboration 
of astrocyte processes [45]. Here we show quantitatively that riluzole has a marked effect on 
astrocytes in a model of neurodegeneration, as shown by its ability to reduce GFAP levels, 
both in the intact and lesioned striatum. Other groups have also suggested that riluzole 
treatment alters astrocyte morphology and GFAP expression in MPTP-treated mice [20,46]. 
It is possible that the ability of riluzole to suppress reactive astrocytosis may contribute to the 
neuroprotective effects observed in this study. As well as glutamate uptake, astrocytes exert a 
number of protective effects on neurones, and riluzole-induced reduction in astrocyte 
reactivity may lead to a suppression of neuroinflammatory pathways, a reduction in oxidative 
stress, hypotheses which can be tested in future studies. 
Methods 
Male Sprague Dawley rats (B & K or Harlan, U.K.) weighing 270 – 300 g were used in these 
studies. Food and water were provided ad libitum. Animals were housed in a temperature- 
and humidity-controlled environment with a 12-h light / dark cycle. All procedures 
conformed to the U.K. Animals (Scientific Procedures) Act, 1986 and institutional ethical 
approval. For unilateral lesions, rats were pre-treated with desipramine (25 mg/kg i.p.) and 
pargyline (5 mg/kg i.p.) 30 minutes prior to induction of isoflurane anaesthesia. In fully 
anesthetised animals, 8 μg 6-OHDA (dissolved in 2.5 μl of 0.02% ascorbic acid/0.9% saline) 
was infused into the right median forebrain bundle (MFB) at a rate of 0.5 μl/min via an 
infusion pump. The stereotaxic coordinates used were: AP: -2.8, ML: +2.0, DV: -9.0 (from 
skull surface) relative to bregma with the incisor bar set at −3.3 mm [4]. Animals were treated 
with riluzole (4 or 8 mg/kg/kg, i.p., Tocris, Avonmouth UK) or PBS vehicle one hour prior to 
the first 6-OHDA injection and daily for 7 days thereafter. 
We chose our lowest dose on the basis of previous work in rodent stroke models which used 
4 mg/kg to see protective effects [32], and the highest dose on the basis of doses which have 
already been suggested to show protection in PD models, for example a recent primate 
studies which used 10 mg/kg riluzole to produce protective effects [25]. 
The extent of motor impairment in animals was assessed using amphetamine-induced 
rotational behaviour testing at 7 days post-lesion. Animals were harnessed in jackets tethered 
to an automated rotometer, placed in 40 cm diameter bowls and recorded for a 10 min 
baseline period before injection of d-amphetamine (5 mg/kg i.p.). Full 360° ipsiversive 
rotations were recorded in 5-min intervals for up to 90 min post-injection for subsequent 
assessment by observers blinded to treatment. 
For immunostaining, on the final day of dosing (day 8), animals were terminally 
anaesthetised using pentobarbital (100 mg/kg) then trans-cardially perfused with 0.1 M PBS, 
followed by 4% paraformaldehyde in 0.1 M PBS. The brains were removed and stored in 
PFA at 4°C. Coronal sections (15 μm) were cut on a vibrating microtome and free floating 
sections were incubated with blocking buffer (1% normal goat serum in 0.1 M PBS) then 
overnight with rabbit anti -tyrosine hydroxylase (TH) antibody (1:1250; Chemicon), rabbit 
anti-glial fibrillary acidic protein (GFAP) antibody (1:1000, Dako), rabbit anti-GLT-1 
(1:4000, gift of D. Pow, Brisbane). After three PBS washes, sections were incubated for 1 h 
with secondary antibody (biotinylated goat anti-rabbit 1:200; Sigma) then incubated for 30 
min with an ABC kit (Vector Labs) and the signal developed in 10% diaminobenzidine 
tetrahydrochloride (DAB) in Tris-buffered saline for 10 min. In some experiments, the 
fluorescent secondary antibody, anti-rabbit Alexa 488 (1:1000) (Invitrogen, Paisley, UK) was 
used. Immunostained sections were viewed on a Zeiss apotome microscope and recorded 
using Axiovision LE software (Carl Zeiss Ltd., Hertfordshire, UK) at 50x magnification. To 
obtain cell counts in the substantia nigra pars compacta (SNpc), only viable TH-positive cells 
(i.e. intact round cells displaying a clear nucleus and cytoplasm) were counted in each 
hemisphere using image analysis software (Image J, NIH, Bethesda, MD). Previous studies 
have shown that data obtained using full stereological counting and manual counting of TH-
positive cells in the SNpc in the 6-OHDA rat model are indistinguishable [47], so manual 
counting was adopted here. For each animal, the numbers of cells in three adjacent sections 
of SNpc was counted in both ipsilateral and contralateral hemispheres at three different 
rostrocaudal level (−4.8, −5.3, and −5.8 mm AP from Bregma), and averaged to give a mean 
cell count per section for the ipsilateral and contralateral sides. TH-positive cell counts in the 
6-OHDA lesioned side, expressed as % of the contralateral, intact hemisphere, were 
compared between treatment groups using a One-way ANOVA and Bonferroni post-hoc test. 
For Western blotting, on the final day of dosing rats were killed by terminal anaesthesia, and 
the brains rapidly dissected and regions frozen on dry ice. Western blotting of samples was 
carried out as described elsewhere [48]. Membranes were incubated with the following 
antibodies: rabbit anti GFAP (1:1000, Dako), rabbit anti-GLT-1 (1:4000, gift of D. Pow, 
Brisbane) or mouse anti-beta tubulin (1:400, Sigma-Aldrich). Detection was carried out using 
a horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse IgG, as appropriate 
(1:1000, Sigma) using ECL Western blotting detection reagents and film detection (GE 
Healthcare). Bands were analysed using ImageJ (NIH, Bethesda, MD). GLT-1 quantification 
was obtained by quantifying both the lower (monomeric) and the high molecular mass 
(multimeric) bands, as described previously [49]. 
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